Total
0
Shares
MediPharm Labs - Asia Pacific CEO, Warren Everitt
Asia Pacific CEO, Warren Everitt
Source: South Gippsland Sentinel Times
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm Labs (LABS) has completed another GMP cannabis extract delivery to German partner Vayamed
  • This delivery confirms MediPharm’s position as a leader in the wholesale of GMP cannabis oil to the European Union’s largest medical cannabis jurisdiction
  • MediPharm looks forward to completing more deliverys to Vayamed under their partnership agreement
  • MediPharm develops and manufactures cannabis concentrates, active pharmaceutical ingredients and advanced derivative products
  • MediPharm Labs Corp. (LABS) opened trading at C$0.255 per share

MediPharm Labs (LABS) has completed another GMP cannabis extract delivery to Germany.

This delivery of formulated oil bottles further establishes MediPharm’s position as a leader in the wholesale of GMP cannabis oil to the European Union’s largest medical cannabis jurisdiction. 

The cannabis extract has been shipped to Vayamed from MediPharm’s GMP facility in Australia. MediPharm’s Australian operations have been licensed by the Office of Drug Control and Therapeutic Goods Administration of the Australian Government’s Department of Health, which has allowed MediPharm to unlock markets with strict regulatory requirements, including Australia and the European Union.

“As a pharmaceutical company specializing in precision-based cannabinoids MediPharm Labs continues to execute on delivering to its international partners. Making the deliveries to a leading company like Vayamed shows not only the demand for our quality products but the ability to navigate the complex regulations of international medical cannabis trade,” said Warren Everitt, CEO Asia Pacific, MediPharm Labs.

“It further demonstrates the value provided by our Australian business, which is already becoming a key asset for the company as it continues to ship GMP product to a growing international market.”

“MediPharm Labs convinced us with a high level of product competence and a company philosophy that fits perfectly to our portfolio strategy and with the brand vision of Vayamed: Medicine from Nature – customized for patients,” says Thimo V. Schmitt-Lord, Director Market Development & Sector Innovation, Vayamed, who is responsible for the company’s strategic portfolio development.

The company looks forward to completing additional deliveries to Vayamed under the partnership agreement. MediPharm develops and manufactures cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.

MediPharm Labs Corp. (LABS) opened trading at C$0.255 per share.

More From The Market Herald
Ovation Science Inc - President and CEO, Terry Howlett

" Ovation (CSE:OVAT) provides update on its topical cannabis research and development

Ovation Science (OVAT) has developed new high-dose CBD formulations for both its beauty, and health and wellness lines.
The Market Herald Video

" Adastra Holdings (CSE:XTRX) reports record third-quarter results

Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.

" Tilray (TSX:TLRY) launches Medical Cannabis oral strips

Tilray (TLRY) makes medical cannabis oral strips powered by QuickStrip™ technology available to patients.

" InterCure (TSX:INCR.U) partners with cannabis brand Cookies

To facilitate its expansion into Europe, InterCure (INCR.U) has announced a partnership with iconic cannabis brand Cookies.